Company news

GSK plc news in 2024

GSK plc's news releases, calls and decks from 2024, newest first.

View company

Headline results from phase III FIRST trial

December 20, 2024

Jemperli receives US FDA breakthrough designation

December 16, 2024

EMA grants PRIME Designation for GSK’227

December 16, 2024

Jemperli receives positive CHMP opinion

December 16, 2024

Overall survival data presented for Blenrep

December 9, 2024

Blenrep combination China filing acceptance

December 9, 2024

Nucala COPD submission accepted by US FDA

December 9, 2024

Zhifei China collaboration revised and extended

December 5, 2024

GSK liquid meningitis vaccine authorised in EU

November 27, 2024

Blenrep combinations accepted for US FDA review

November 25, 2024

Japan approves first RSV vaccine for adults 50-59

November 22, 2024

GLISTEN Trial of Linerixibat Meets Endpoint

November 19, 2024

GSK announces overall survival results for Blenrep

November 14, 2024

GSK publishes provisional 2025 dividend dates

November 11, 2024

New positive Arexvy data in younger adults at risk

October 24, 2024

FDA accepts new drug application for gepotidacin

October 16, 2024

Positive results of ANCHOR trials of depemokimab

October 14, 2024

Zantac (ranitidine) litigation settlements

October 9, 2024

Positive efficacy data of Arexvy over 3 seasons

October 8, 2024

Positive EU opinion for GSK liquid Menveo vaccine

September 24, 2024

Statement: Zantac (ranitidine) litigation

September 18, 2024

Japan Filing Acceptance: Blenrep Multiple Myeloma

September 17, 2024

China Breakthrough Therapy Designation for Blenrep

September 13, 2024

Positive mRNA flu vaccine Phase II headline data

September 12, 2024

Change of Registered Office

September 11, 2024

Update on phase I/II therapeutic HSV vaccine trial

September 11, 2024

Depemokimab late-breaking data presented at ERS

September 9, 2024

Positive Phase III results for Nucala in COPD

September 6, 2024

EMA approval on Arexvy for 50-59 at risk

August 29, 2024

SENKU Designation for Bepirovirsen in Japan

August 28, 2024

Nucala approved in Japan for use in CRSwNP

August 28, 2024

B7-H3 ADC US FDA Breakthrough Therapy Designation

August 20, 2024

FDA Expands Jemperli Approval

August 2, 2024

CHMP positive opinion on Arexvy for 50-59 at risk

July 29, 2024

Blenrep EMA Filing Acceptance

July 19, 2024

GSK and CureVac collaboration restructured

July 3, 2024

Omjjara approved in Japan for myelofibrosis

June 24, 2024

EMA validates Jemperli marketing authorisation

June 24, 2024

FDA approves Arexvy for adults 50-59 at risk

June 10, 2024

Unprecedented results in Jemperli trial continue

June 3, 2024

ASCO positive Blenrep DREAMM-8 trial results

June 3, 2024

Positive phase III asthma results for depemokimab

May 21, 2024

GSK completes sale of shares in Haleon plc

May 17, 2024

GSK announces intention to sell shares in Haleon

May 16, 2024

US FDA accepts new indication filing for Jemperli

April 24, 2024

GSK announces additional EAGLE-1 results

April 17, 2024

Results from long-term data relating to Shingrix

April 17, 2024

Amendment - Director/PDMR Shareholding

April 16, 2024

FDA accepts GSK meningitis vaccine candidate file

April 16, 2024

Replacement - Total Voting Rights

April 4, 2024

Older news releases →

Calls in 2024

Decks in 2024